

# Summary of Studies Supporting USDA Product Licensure

Establishment Name	Epitopix, LLC
USDA Vet Biologics Establishment Number	365
Product Code	27A5.02
True Name	Salmonella Enteritidis Bacterial Extract
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Vaxxon SRP SE - No distributor specified
Date of Compilation Summary	January 10, 2020

#### Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy					
Pertaining to	Salmonella	Enteritidis	5			
Study Purpose	To demonstrate effectiveness against <i>Salmonella</i> Enteritidis in chickens.					
Product Administration	Two doses administered at an 8-week interval by subcutaneous					
	injection.					
Study Animals		ld chicken	s were rando	omly assig	med to one	of two
	Ten week old chickens were randomly assigned to one of two treatments, vaccinates (21 birds) or placebo (29 birds).					
Challenge Description	All chickens were challenged with <i>Salmonella enterica</i>					
	Enteritidis 28 days following second vaccination.					
Interval observed after			onitored for			be then
challenge	tissues were					5
Results	A chicken was considered affected if the ovary or oviduct had a bacterial count of <i>Salmonella</i> Enteritidis >0.				uct had a	
	bacterial co	unt of Sali	nonella Ente	eritiais <u>&gt;</u> 0.		
	Summary					
		Salmon	ella	Salmo	nella	
	Enteritidis Negative Enteritidis Positive					
	Placebo 22 7					
	Vaccinates 21 0					
	Raw Data Salmonella Enteritidis Culture Data (CFU/gram) of Ovary/Oviduct					
	Placebo Culture Placebo Culture Culture					
	Animal	Data	Animal	Data	Animal	Data
	ID ID ID ID				Dutu	
	111	2000	152	0	186	0
					0	
	118 0 167 0 188 10				10	
	122	0	173	0	190	0
	127	0	174	0	196	0
	129	0	175	0	197	0
	133 0 176 300 198 10					
	<u>136</u> 0 <u>177</u> <u>11000</u> <u>199</u> 0					
	<u>143</u> 0 <u>180</u> 10 <u>200</u> 0					
	All vaccinates were negative for culture of Salmonella Enteritidis.					
USDA Approval Date	November	1, 2016				

Study Type	Safety			
Pertaining to	ALL			
Study Purpose	To demonstrate safety of the product under field conditions.			
Product Administration	Two doses administered at a 3-8 week interval by a			
	subcutaneous route of injection.			
Study Animals	A total of 111,058 chickens were enrolled in the study and			
	housed at commercial egg or layer operations in three			
	geographically distinct regions of the United States. The			
	chickens were vaccinated with the test vaccine or left as non-			
	vaccinated controls. Birds ranged in age from 8 weeks to 15			
	weeks at first vaccination.			
Challenge Description	Not applicable			
Interval observed after	Chickens were observed for adverse events and mortality for 21			
challenge	days after each of two vaccinations given 3-8 weeks apart.			
Results	No adverse events were observed in any chickens after			
	vaccination.			
	Mortality rates are listed in tables by region below.			
USDA Approval Date	July 10, 2019			

### Tables show the mortality of chickens at each site after each vaccination.

Region 1

Treatment	Starting	21-day	Mortality Rate (%)
	Population	Mortality	
1 <sup>st</sup> Vaccination			
Vaccine Serial	22,748	43	0.19
Control	22,939	35	0.15
2 <sup>nd</sup> Vaccination	·	•	
Vaccine Serial	22,671	39	0.17
Control	22,889	18	0.08

### Region 2

Treatment	Starting	21-day	Mortality Rate (%)
	Population	Mortality	
1 <sup>st</sup> Vaccination	·	·	
Vaccine Serial	12,885	46	0.36
Control	12,947	26	0.20
2 <sup>nd</sup> Vaccination			
Vaccine Serial	12,839	51	0.40
Control	12,921	23	0.18

## Region 3

Treatment	Starting	21-day	Mortality Rate (%)
	Population	Mortality	
1 <sup>st</sup> Vaccination			
Vaccine Serial	19,811	74	0.37
Control	19,728	80	0.41
2 <sup>nd</sup> Vaccination			
Vaccine Serial	19,710	37	0.19
Control	19,516	48	0.25